RESUMO
OBJECTIVES: To determine if patients managed with a cystectomy enhanced recovery pathway (CERP) have improved quality of care after radical cystectomy (RC), as defined by a decrease in length of hospital stay (LOS) without an increase in complications or readmissions compared with those not managed with CERP. SUBJECTS AND METHODS: The Quality Improvement in Cystectomy Care with Enhanced Recovery (QUICCER) study was a non-randomized quasi-experimental study. Data were collected between June 2011 and April 2015. The CERP was implemented in July 2013. The primary endpoint was LOS. Secondary endpoints were quality scores, complications and readmissions. Multivariable regression was performed. Propensity score matching was carried out to further simulate randomized clinical trial conditions. A CERP quality composite score was created and evaluated with regard to adherence to CERP elements. RESULTS: The study included 79 patients managed with CERP and 121 who were not managed with CERP. After matching, there were 75 patients in the non-CERP group. The LOS was significantly different between the groups: the median LOS was 5 and 8 days for the CERP and non-CERP group, respectively (P < 0.001). Multivariable linear regression showed that any complication was the most significant predictor of total LOS at 90 days after RC. The higher the quality composite score the shorter the LOS (P < 0.001). There was no association between CERP and a greater number of complications or readmissions. CONCLUSIONS: Audited quality measures in the CERP are associated with a reduction in LOS with no increase in readmissions or complications. The CERP is important for the future improvement of peri-operative care for RC and provides an opportunity to improve the quality of care provided.
Assuntos
Assistência ao Convalescente/normas , Cistectomia , Melhoria de Qualidade , Idoso , Procedimentos Clínicos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Recuperação de Função FisiológicaRESUMO
Cystectomy is a complex procedure with a tenuous perioperative course. Enhanced recovery programs (ERPs) are bundle strategies, developed to enhance the recovery of surgical patients. This article outlines the components of an ERP for cystectomy patients from a nursing implementation perspective.
Assuntos
Cistectomia/enfermagem , Estomia/enfermagem , Dor Pós-Operatória/enfermagem , Assistência Perioperatória/enfermagem , Neoplasias da Bexiga Urinária/cirurgia , Derivação Urinária/enfermagem , Protocolos Clínicos , Humanos , Tempo de Internação , Manejo da Dor , Neoplasias da Bexiga Urinária/enfermagemRESUMO
Interstitial cystitis (IC) is a chronic inflammatory condition characterized by urinary frequency, urgency, and pain in the bladder or pelvis that for some can be debilitating. At present, IC is without cure, yet various management modalities are available. This article provides a general overview of the history, symptoms, diagnosis, and treatment of IC. A specific case study that focuses on a surgical management option is highlighted.
Assuntos
Cistite Intersticial/cirurgia , Derivação Urinária/enfermagem , Cistite Intersticial/diagnóstico , Cistite Intersticial/terapia , Feminino , Humanos , Pessoa de Meia-Idade , Assistência Perioperatória/enfermagem , Derivação Urinária/reabilitaçãoRESUMO
Schistosomiasis is a parasitic infection caused by trematodes (flatworms). It is second only to malaria in public health significance, with an estimated 200 million people infected worldwide. Schistosoma haematobium is endemic in Africa and the Middle East. This case study discusses a 36-year-old Somalian male who immigrated to a Northeastern city in the United States from a refugee camp in Kenya. He presented with episodic gross hematuria and flank pain, and was eventually diagnosed with urinary tract schistosomiasis, which was successfully treated with praziquantel. While the disease is not common in the United States, this case is presented for both its urological and cultural considerations.
Assuntos
Esquistossomose Urinária , Adulto , Anti-Helmínticos/uso terapêutico , Dor no Flanco/etiologia , Hematúria/etiologia , Humanos , Masculino , Praziquantel/uso terapêutico , Refugiados , Esquistossomose Urinária/complicações , Esquistossomose Urinária/diagnóstico , Esquistossomose Urinária/tratamento farmacológico , Esquistossomose Urinária/fisiopatologia , Somália/etnologia , Estados UnidosRESUMO
The management of prostate cancer includes observation, hormonal therapy, radical prostate surgery (open, laparoscopic, or laparoscopic robotic), external beam radiation, brachytherapy, or cryotherapy. Laparoscopic radical robotic prostatectomy is the newest technology in minimally invasive surgery. This is a case study of a patient who chose to undergo laparoscopic robotic prostatectomy for his prostate cancer.
Assuntos
Adenocarcinoma/cirurgia , Laparoscopia/métodos , Assistência Perioperatória , Prostatectomia/métodos , Neoplasias da Próstata/cirurgia , Adenocarcinoma/diagnóstico , Adenocarcinoma/enfermagem , Adenocarcinoma/psicologia , Biópsia , Humanos , Laparoscopia/enfermagem , Laparoscopia/psicologia , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Alta do Paciente , Educação de Pacientes como Assunto , Satisfação do Paciente , Assistência Perioperatória/métodos , Assistência Perioperatória/enfermagem , Prostatectomia/enfermagem , Prostatectomia/psicologia , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/psicologia , Robótica , Resultado do Tratamento , Cateterismo UrinárioRESUMO
PURPOSE: To examine the association between extended-duration prophylaxis (EDP), low-molecular-weight heparin prophylaxis for 28 days after surgery for urologic cancer in patients at high risk of developing a venous thromboembolism (VTE), the risk of VTE, and the complications resulting from VTE prophylaxis. MATERIALS AND METHODS: The cohort included 332 patients at high risk for VTE who were surgically treated for urologic cancer from June 2011 to June 2014. Adherence to VTE prophylaxis protocol, VTEs, and complications within 365 days from surgery were tracked. Patients were grouped as follows: (1) per protocol in-hospital prophylaxis with EDP (n = 107), (2) per protocol in-hospital prophylaxis without EDP (n = 42), (3) not per protocol in-hospital prophylaxis with EDP (n = 83), and (4) not per protocol in-hospital prophylaxis without EDP (n = 100). The risk of VTE was compared between the 4 groups using the Cox model, with adjustment for baseline risk factors. RESULTS: The rates of VTEs and median times to VTE were 7% and 58 days in group 1, 17% and 44 days in group 2, 17% and 46 days in group 3, and 21% and 15 days in group 4, respectively. Adjusted hazard ratios (HR) for VTE were HR = 0.27 (95% CI: 0.11-0.70) for groups 1 vs. 4; HR = 0.66 (95% CI: 0.25-1.60) for groups 2 vs. 4; and HR = 0.66 (95% CI: 0.29-1.26) for groups 3 vs. 4 with a trend of P = 0.002. The incidence of complications from VTE prophylaxis was not significantly different between the groups, with a rate of 8% in group 1, 17% in group 2, 6% in group 3, and 12% in group 4 (P = 0.33). CONCLUSIONS: In high-risk urologic cancer surgery patients, a clinical protocol, with perioperative and EDP, is safe and effective in reducing VTE events.
Assuntos
Anticoagulantes/administração & dosagem , Heparina de Baixo Peso Molecular/administração & dosagem , Complicações Pós-Operatórias/prevenção & controle , Procedimentos Cirúrgicos Urológicos/efeitos adversos , Tromboembolia Venosa/prevenção & controle , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Urológicas/cirurgia , Tromboembolia Venosa/etiologiaRESUMO
BACKGROUND: Appropriate timing of androgen deprivation treatment (ADT) for prostate cancer is controversial. Our aim was to determine whether immediate ADT extends survival in men with node-positive prostate cancer who have undergone radical prostatectomy and pelvic lymphadenectomy compared with those who received ADT only once disease progressed. METHODS: Eligible patients from 36 institutes in the USA were randomly assigned in 1988-93 to receive immediate ADT (n=47) or to be observed (n=51), with ADT to be given on detection of distant metastases or symptomatic recurrences. Patients were followed up every 3 months for the first year and every 6 months thereafter. The primary endpoint was progression-free survival; secondary endpoints were overall and disease-specific survival. Analysis was by intention to treat. To ensure that the treatment groups were comparable, we did a retrospective central pathology review of slides and regraded the Gleason scores for available samples. This trial predates the requirement for clinical trial registration. FINDINGS: At median follow-up of 11.9 years (range 9.7-14.5 for surviving patients), men assigned immediate ADT had a significant improvement in overall survival (hazard ratio 1.84 [95% CI 1.01-3.35], p=0.04), prostate-cancer-specific survival (4.09 [1.76-9.49], p=0.0004), and progression-free survival (3.42 [1.96-5.98], p<0.0001). Of 49 histopathology slides received (19 immediate ADT, 30 observation), 16 were downgraded from the original Gleason score (between groups < or = 6, 7, and > or = 8) and five were upgraded. We recorded similar proportions of score changes in each group (p=0.68), and no difference in score distribution by treatment (p=0.38). After adjustment for score, associations were still significant between treatment and survival (overall, p=0.02; disease-specific, p=0.002; progression-free survival, p<0.0001). INTERPRETATION: Early ADT benefits patients with nodal metastases who have undergone prostatectomy and lymphadenectomy, compared with those who receive deferred treatment. The beneficial effects of early ADT, rather than an imbalance in risk factors, are likely to explain the differences in outcomes between treatments.
Assuntos
Antagonistas de Androgênios/uso terapêutico , Antineoplásicos Hormonais/uso terapêutico , Excisão de Linfonodo , Recidiva Local de Neoplasia/prevenção & controle , Prostatectomia , Neoplasias da Próstata/tratamento farmacológico , Idoso , Antagonistas de Androgênios/administração & dosagem , Antineoplásicos Hormonais/administração & dosagem , Terapia Combinada , Intervalo Livre de Doença , Esquema de Medicação , Seguimentos , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Estadiamento de Neoplasias , Pelve , Neoplasias da Próstata/patologia , Neoplasias da Próstata/cirurgia , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
OBJECTIVES: To determine the clinical association between urinary glycosaminoglycan (GAG) concentration and kidney stone disease. METHODS: Thirty-five patients (14 women and 21 men) with a history of stone disease and 37 controls (13 women and 24 men) were evaluated for urinary GAG concentration. By using a new dye-binding assay, the total GAG concentration in the urine was measured and corrected to urinary creatinine levels (micrograms of GAG per milligram creatinine). RESULTS: The mean urinary GAG concentration in those with stones was significantly lower (31.5 +/- 2.6 microg GAG/mg creatinine) than in the controls (43.8 +/- 3.8 microg GAG/mg creatinine, P = 0.01). Male patients with stones also had a significantly lower mean GAG concentration (26.1 +/- 1.8) than did the female patients (39.6 +/- 5.3, P = 0.009). The mean GAG concentration between ureteral (n = 13) versus renal (n = 22), single (n = 19) versus multiple (n = 16), family history (n = 11) versus no family history (n = 24), large (n = 13) versus small (n = 20), and the presence (n = 22) versus absence (n = 13) of residual stones did not show any significant differences. However, patients with recurrent stone formation (n = 21) had significantly lower mean GAG levels (26.4 +/- 1.6) compared with those with single stone formation (n = 14; 39.2 +/- 5.5, P = 0.01). CONCLUSIONS: Lower urinary GAG levels are more common in patients with stone formation. This may play a more determinant role in male patients and those with recurrent stone formation.